{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T01:37:21Z","timestamp":1720057041917},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.drugalcdep.2015.05.021","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T01:15:03Z","timestamp":1432862103000},"page":"201-206","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users"],"prefix":"10.1016","volume":"153","author":[{"given":"Jermaine D.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared J.","family":"Atchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Madera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena E.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0005","series-title":"6 Row-Column Designs and 9 More about Latin Squares. Design of Comparative Experiments","author":"Bailey","year":"2008"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0010","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.1360-0443.2005.01089.x","article-title":"Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain","volume":"100","author":"Brugal","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0015","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1553-2712.2006.tb01006.x","article-title":"Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: analysis of medical examiner data","volume":"13","author":"Chan","year":"2006","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0020","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"American Pain Society\u2013American Academy of Pain Medicine Opioids Guideline Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J. Pain"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0035","series-title":"Shifting the Paradigm: A Blueprint for Value Recognition and Process Improvement in the U.S. Drug Testing Market","author":"Christensen","year":"2014"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5694\/j.1326-5377.1997.tb138794.x","article-title":"Heroin related deaths in south western Sydney","volume":"167","author":"Darke","year":"1997","journal-title":"Med. J. Aust."},{"issue":"August 21 (162)","key":"10.1016\/j.drugalcdep.2015.05.021_bib0045","first-page":"43876","article-title":"U.S. Federal Register Notice to Revise the Mandatory Guidances for Specimen Validity Testing","volume":"66","author":"Federal Register","year":"2001","journal-title":"Federal Register"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0050","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1570-0232(02)00925-X","article-title":"Clinical use of polyethylene glycols as marker substances and determination in urine by liquid chromatography","volume":"787","author":"Gauchel","year":"2003","journal-title":"J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0055","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1403494812472007","article-title":"Diversity in causes and characteristics of drug-induced deaths in an urban setting","volume":"41","author":"Gjersing","year":"2013","journal-title":"Scand. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0060","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3810\/pgm.2013.07.2684","article-title":"Risks, management, and monitoring of combination opioid, benzodiazepines, and\/or alcohol use","volume":"125","author":"Gudin","year":"2013","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0065","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/alcalc\/agn084","article-title":"Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification","volume":"44","author":"Helander","year":"2009","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0070","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(96)05336-6","article-title":"Testing for drug abuse","volume":"348","author":"Honour","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0075","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1515\/CCLM.2004.107","article-title":"Urine labeling with orally applied marker substances in drug substitution therapy","volume":"42","author":"Huppertz","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0080","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jsat.2006.11.008","article-title":"Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing","volume":"33","author":"Jaffee","year":"2007","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0085","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug. Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0090","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug. Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0095","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/npp.2010.172","article-title":"The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine\/naloxone","volume":"36","author":"Jones","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0100","article-title":"Abuse potential of intranasal buprenorphine versus buprenorphine\/naloxone in buprenorphine-maintained heroin users","author":"Jones","year":"2014","journal-title":"Addict. Biol."},{"issue":"2\u20133","key":"10.1016\/j.drugalcdep.2015.05.021_bib0103","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.drugalcdep.2007.05.019","article-title":"Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients","volume":"91","author":"Lintzeris","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0104","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"16","author":"Mattick","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl. 3","key":"10.1016\/j.drugalcdep.2015.05.021_bib0105","first-page":"S67","article-title":"American Society of Interventional Pain Physicians. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2\u2014Guidance","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Phys."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0110","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jsat.2010.01.006","article-title":"Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment","volume":"38","author":"Me\u2019garbane","year":"2010","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0119","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1093\/clinchem\/34.11.2333","article-title":"Adulterants causing false negatives in illicit drug testing","volume":"34","author":"Mikkelsen","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0120","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/10550880903014767","article-title":"Diversion of buprenorphine\/naloxone coformulated tablets in a region with high prescribing prevalence","volume":"28","author":"Monte","year":"2009","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0125","series-title":"Unintentional Drug Poisoning (Overdose) Deaths in New York City, 2000\u20132012","author":"New York City Department of Health and Mental Hygiene","year":"2013"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0130","first-page":"ES119","article-title":"Urine drug testing: current recommendations and best practices","volume":"15","author":"Owen","year":"2012","journal-title":"Pain Phys."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0135","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1360-0443.2004.00790.x","article-title":"A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone associated deaths","volume":"99","author":"Pirnay","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0140","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1046\/j.1360-0443.1998.93913859.x","article-title":"Six deaths linked to concomitant use of buprenorphine and benzodiazepines","volume":"93","author":"Reynaud","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0145","series-title":"Clinical Drug Testing in Primary Care","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2012"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0150","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/10550887.2012.694603","article-title":"Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine\/naloxone in marginalized populations","volume":"31","author":"Stancliff","year":"2012","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0154","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1046\/j.1360-0443.2000.951217858.x","article-title":"The nature of benzodiazepine dependence among heroin users in Sydney, Australia","volume":"95","author":"Ross","year":"2000","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0155","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1521-0391.2013.12058.x","article-title":"Hepatitis C infection in non-treatment seeking heroin users: the burden of cocaine injection","volume":"22","author":"Roux","year":"2013","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0160","series-title":"FDA Acts to Reduce Harm from Opioid Drugs. Washington, DC. Updated April 2013","author":"U.S. Food and Drug Administration (FDA)","year":"2011"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0165","series-title":"Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain","author":"Utah Department of Health","year":"2009"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0170","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1055\/s-2001-18032","article-title":"Death attributed to methadone","volume":"34","author":"Vormfelde","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0175","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/00007691-200208000-00001","article-title":"Characterization of methadone overdose: clinical considerations and the scientific evidence","volume":"24","author":"Wolff","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.drugalcdep.2015.05.021_bib0180","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5694\/j.1326-5377.1996.tb94136.x","article-title":"Heroin-related deaths in New South Wales, 1992: toxicological findings and circumstances","volume":"164","author":"Zador","year":"1996","journal-title":"Med. J. Aust."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871615002574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871615002574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T20:32:35Z","timestamp":1599078755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871615002574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":37,"alternative-id":["S0376871615002574"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.05.021","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}